IDH2 and glioma: H3F3A/B (H3.3 G34R/V mutated protein) mutated tumors [176,177] comprise a histologically heterogeneous group of gliomas, usually in adolescent patients, with a marginally better clinical outcome compared to other IDH-wildtype GBM.